Biomarker blood tests for diagnosis and management of mental disorders: Focus on schizophrenia;Testes sanguíneos de biomarcadores para diagnóstico e tratamento de desordens mentais: Foco em esquizofrenia

Revista de Psiquiatria Clinica

Volumn 40, Issue 1, 2013, Pages 2-9

  Bahn, Sabine ^a,b   Schwarz, Emanuel ^a   Harris, Laura W ^a   Martins de Souza, Daniel ^a,c,d   Rahmoune, Hassan ^a   Guest, Paul C ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF MUNICH   (Germany)

^d UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Biomarkers; Diagnosis; Psychiatric disorders; Regulatory authorities; Schizophrenia

Indexed keywords

BIOLOGICAL MARKER;

CLINICAL DECISION MAKING; DSM-IV; GENERAL PRACTITIONER; GENETIC ASSOCIATION; GENOMICS; HUMAN; IMMUNOASSAY; POSITIVE AND NEGATIVE SYNDROME SCALE; PROTEIN EXPRESSION; PSYCHIATRIST; REVIEW; SCHIZOPHRENIA; STANDARDIZATION;

EID: 84874388240     PISSN: 01016083     EISSN: 1806938X     Source Type: Journal    
DOI: None     Document Type: Review

References (81)

1. Schaffer D. A participant's observations: preparing DSM-IV. Can J Psychiatry. 1996;41:325-9.
2. Ovens J. Funding for accelerating drug development initiative critical. Nat Rev Drug Discov. 2006;5:271.
3. Marson B. "Critical Path" is on the road forward; FDA reports industry activity is high. The Pink Sheet. 2007;69:29.
4. Goodsaid F, Frueh FW. Implementing the U.S. FDA guidance on pharmacogenomic data submissions. Environ Mol Mutagen. 2007;48:354-8.
5. Schwarz E, Izmailov R, Spain M, Barnes A, Mapes JP, Guest PC, et al. Validation of a blood-based laboratory test to aid in the confirmation of a diagnosis of schizophrenia. Biomark Insights. 2010;5:39-47.
6. Tsuang MT. Heterogeneity of schizophrenia. Biol Psychiatry. 1975;10:465-74.
7. Gonzalez-Pinto A, Gutierrez M, Mosquera F, Ballesteros J, Lopez P, Ezcurra J, et al. First episode in bipolar disorder: misdiagnosis and psychotic symptoms. J Affect Disord. 1998;50:41-4.
8. Follette WC, Houts AC. Models of scientific progress and the role of theory in taxonomy development: a case study of the DSM. J Consult Clin Psychol. 1996;64:1120-32.
9. Wakefield JC. Misdiagnosing normality: psychiatry's failure to address the problem of false positive diagnoses of mental disorder in a changing professional environment. J Ment Health. 2010;19:337-51.
10. Strakowski SM, Keck PE Jr, Arnold LM, Collins J, Wilson RM, Fleck DE, et al. Ethnicity and diagnosis in patients with affective disorders. J Clin Psychiatry. 2003;64:747-54.
11. Cheniaux E, Landeira-Fernandez J, Versiani M. The diagnoses of schizophrenia, schizoaffective disorder, bipolar disorder and unipolar depression: interrater reliability and congruence between DSM-IV and ICD-10. Psychopathology. 2009;42:293-8.
12. Yolken RH, Dickerson FB, Fuller Torrey E. Toxoplasma and schizophrenia. Parasite Immunol. 2009;31:706-15.
13. Lovatt A, Mason O, Brett C, Peters E. Psychotic-like experiences, appraisals, and trauma. J Nerv Ment Dis. 2010;198:813-9.
14. Bagby RM, Rogers R, Buis T, Nicholson RA, Cameron SL, Rector NA, et al. Detecting feigned depression and schizophrenia on the MMPI-2. J Pers Assess. 1997;68:650-64.
15. Robins E, Guze SB. Establishment of diagnostic validity in psychiatric illness: its application to schizophrenia. Am J Psychiatry. 1970;126:983-7.
16. Schwartz JE, Fennig S, Tanenberg-Karant M, Carlson G, Craig T, Galambos N, et al. Congruence of diagnoses 2 years after a first-admission diagnosis of psychosis. Arch Gen Psychiatry. 2000;57:593-600.
17. Castagnini A, Bertelsen A, Berrios GE. Incidence and diagnostic stability of ICD-10 acute and transient psychotic disorders. Compr Psychiatry. 2008;49(3):255-61.
18. Clayton PJ, Guze SB, Cloninger CR, Martin RL. Unipolar depression: diagnostic inconsistency and its implications. J Affect Disord. 1992;26:111-6.
19. Bromet EJ, Kotov R, Fochtmann LJ, Carlson GA, Tanenberg-Karant M, Ruggero C, et al. Diagnostic shifts during the decade following first admission for psychosis. Am J Psychiatry. 2011;168(11):1186-94.
20. Torrey EF. Are we overestimating the genetic contribution to schizophrenia? Schizophr Bull. 1992;18:159-70.
21. McGue M. When assessing twin concordance, use the probandwise not the pairwise rate. Schizophr Bull. 1992;18:171-6.
22. Tsuang M. Schizophrenia: genes and environment. Biol Psychiatry. 2000;47:210-20.
23. Dauncey MJ, Bicknell RJ. Nutrition and neurodevelopment: mechanisms of developmental dysfunction and disease in later life. Nutr Res Rev. 1999;12:231-53.
24. Schlotz W, Phillips DI. Fetal origins of mental health: evidence and mechanisms. Brain Behav Immun. 2009;23:905-16.
25. Koenig JI, Kirkpatrick B, Lee P. Glucocorticoid hormones and early brain development in schizophrenia. Neuropsychopharmacology. 2002;27:309-18.
26. Ryan MC, Collins P, Thakore JH. Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. Am J Psychiatry. 2003;160:284-9.
27. Spelman LM, Walsh PI, Sharifi N, Collins P, Thakore JH. Impaired glucose tolerance in first-episode drug-naive patients with schizophrenia. Diabet Med. 2007;24:481-45.
28. Guest PC, Wang L, Harris LW, Burling K, Levin Y, Ernst A, et al. Increased levels of circulating insulin-related peptides in first-onset, antipsychotic naive schizophrenia patients. Mol Psychiatry. 2010;15:118-9.
29. Szulc A, Galińska B, Konarzewska B, Gudel-Trochimowicz I, Popławska R. Immunological marker activity in first episode schizophrenic patients. Pol Merkur Lekarski. 2001;10:450-2.
30. Van Venrooij JA, Fluitman SB, Lijmer JG, Kavelaars A, Heijnen CJ, Westenberg HG, et al. Impaired neuroendocrine and immune response to acute stress in medication-naive patients with a first episode of psychosis. Schizophr Bull. 2012;38(2):272-9.
31. Schwarz E, Guest PC, Rahmoune H, Martins-de-Souza D, Niebuhr DW, Weber NS, et al. Identification of a blood-based biological signature in subjects with psychiatric disorders prior to clinical manifestation. World J Biol Psychiatry. 2011. (in press)
32. Agius M, Shah S, Ramkisson R, Murphy S, Zaman R. Three year outcomes of an early intervention for psychosis service as compared with treatment as usual for first psychotic episodes in a standard community mental health team. Preliminary results. Psychiatr Danub. 2007;19:10-9.
33. Salokangas RK, McGlashan TH. Early detection and intervention of psychosis. A review. Nord J Psychiatry. 2008;62:92-105.
34. Yap HL. Early psychosis intervention. Singapore Med J. 2010;51;689-93.
35. Thomas P. The many forms of bipolar disorder: a modern look at an old illness. J Affect Disord. 2004;79(Suppl 1):S3-8.
36. Hirschfeld RM. Bipolar spectrum disorder: improving its recognition and diagnosis. J Clin Psychiatry. 2001;62(Suppl 14):5-9.
37. Post RM. The impact of bipolar depression. J Clin Psychiatry. 2005;66(Suppl 5):5-10.
38. Kashshai D, Mate B. The effect of nicotinic acid on the temperature of the skin of patients with schizophrenia in different states. Zh Nevropatol Psikhiatr Im S S Korsakova. 1961;61:1688-98.
39. Vaddadi KS. Niacin flushing and schizophrenia. Med Hypotheses. 1981;7:599-600.
40. Wilson DW, Douglass AB. Niacin skin flush is not diagnostic of schizophrenia. Biol Psychiatry. 1986;21:974-7.
41. Fleeman N, Dundar Y, Dickson R, Jorgensen A, Pushpakom S, McLeod C, et al. Cytochrome P450 testing for prescribing antipsychotics in adults with schizophrenia: systematic review and meta-analyses. Pharmacogenomics J. 2010;11:1-14.
42. Kato M, Serretti A. Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder. Mol Psychiatry. 2010;15:473-500.
43. Desmedt C, Sperinde J, Piette F, Huang W, Jin X, Tan Y, et al. Quantitation of HER2 expression or HER2:HER2 dimers and differential survival in a cohort of metastatic breast cancer patients carefully selected for trastuzumab treatment primarily by FISH. Diagn Mol Pathol. 2009;18:22-9.
44. Spadoni LR, Mclean RB, Herrmann WL. A rapid immunological test for the detection of early pregnancy. West J Surg Obstet Gynecol. 1964;72:92-7.
45. Ball RH, Caughey AB, Malone FD, Nyberg DA, Comstock CH, Saade GR, et al.; First and Second Trimester Evaluation of Risk (FASTER) Research Consortium. First-and second-trimester evaluation of risk for Down syndrome. Obstet Gynecol. 2007;110(1):10-7.
46. Cronin M, Sangli C, Liu ML, Pho M, Dutta D, Nguyen A, et al. Analytical validation of the Oncotype DX genomic diagnostic test for recurrence prognosis and therapeutic response prediction in node-negative, estrogen receptor-positive breast cancer. Clin Chem. 2007;53(6):1084-91.
47. Howey JE, Bennet WM, Browning MC, Jung RT, Fraser CG. Clinical utility of assays of glycosylated haemoglobin and serum fructosamine compared: use of data on biological variation. Diabet Med. 1989;6(9):793-6.
48. Schwarz E, Guest PC, Rahmoune H, Harris LW, Wang L, Leweke FM, et al. Identification of a biological signature for schizophrenia in serum. Mol Psychiatry. 2012;17(5):494-502.
49. Guest PC, Schwarz E, Krishnamurthy D, Harris LW, Leweke FM, Rothermundt M, et al. Altered levels of circulating insulin and other neuroendocrine hormones associated with the onset of schizophrenia. Psychoneuroendocrinology. 2011;36(7):1092-6.
50. Steiner J, Jacobs R, Panteli B, Brauner M, Schiltz K, Bahn S, et al. Acute schizophrenia is accompanied by reduced T cell and increased B cell immunity. Eur Arch Psychiatry Clin Neurosci. 2010;260;509-18.
51. Noll R. The blood of the insane. Hist Psychiatry. 2006;17:395-418.
52. Macphail SR. Clinical observations on the blood of the insane. Br J Psychiatry. 1884;30:378-89.
53. Noll R. American madness: the rise and fall of dementia praecox. Cambridge: Harvard University Press; 2011.
54. Purcell SM, Wray NR, Stone JL, Visscher PM, O'Donovan MC, Sullivan PF, et al.; International Schizophrenia Consortium (2009) Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. Nature. 2009;460:748-52.
55. Shi J, Levinson DF, Duan J, Sanders AR, Zheng Y, Pe'er I, et al. Common variants on chromosome 6p22.1 are associated with schizophrenia. Nature. 2009;460:753-7.
56. Stefansson H, Ophoff RA, Steinberg S, Andreassen OA, Cichon S, Rujescu D, et al. Common variants conferring risk of schizophrenia. Nature. 2009;460:744-7.
57. Flood DG, Marek GJ, Williams M. Developing predictive CSF biomarkers-A challenge critical to success in Alzheimer's disease and neuropsychiatric translational medicine. Biochem Pharmacol. 22011;81(12):1422-34.
58. Gjertson CK, Albertsen PC. Use and assessment of PSA in prostate cancer. Med Clin North Am. 2011;95:191-200.
59. Zhang Z, Chan DW. The road from discovery to clinical diagnostics: lessons learned from the first FDA-cleared in vitro diagnostic multivariate index assay of proteomic biomarkers. Cancer Epidemiol Biomarkers Prev. 2010;19:2995-9.
60. Dieterle F, Sistare F, Goodsaid F, Papaluca M, Ozer JS, Webb CP, et al. Renal biomarker qualification submission: a dialog between the FDAEMEA and Predictive Safety Testing Consortium. Nat Biotechnol. 2010;28:455-62.
61. Truglia JA, Livingston JN, Lockwood DH. Insulin resistance: receptor and post-binding defects in human obesity and non-insulin-dependent diabetes mellitus. Am J Med. 1985;79:13-22.
62. Khristov V. Glucose clamping: a modern method for research on insulin secretion and resistance. Vutr Boles. 1986;25:32-9.
63. Ozer JS, Dieterle F, Troth S, Perentes E, Cordier A, Verdes P, et al. A panel of urinary biomarkers to monitor reversibility of renal injury and a serum marker with improved potential to assess renal function. Nat Biotechnol. 2010;28:486-94.
64. Swain A, Turton J, Scudamore CL, Pereira I, Viswanathan N, Smyth R, et al. Urinary biomarkers in hexachloro-1:3-butadiene-induced acute kidney injury in the female Hanover Wistar rat; correlation of α-glutathione S-transferase, albumin and kidney injury molecule-1 with histopathology and gene expression. J Appl Toxicol. 2011;31(4):366-77.
65. Goodsaid F, Frueh F. Process map proposal for the validation of genomic biomarkers. Pharmacogenomics. 2006;7:773-82.
66. Kamel N, Compton C, Middelveld R, Higenbottam T, Dahlén SE. The Innovative Medicines Initiative (IMI): a new opportunity for scientific collaboration between academia and industry at the European level. Eur Respir J. 2008;31:924-6.
67. Hunter AJ. The Innovative Medicines Initiative: a pre-competitive initiative to enhance the biomedical science base of Europe to expedite the development of new medicines for patients. Drug Discov Today. 2008;13:371-3.
68. Ellington AA, Kullo IJ, Bailey KR, Klee GG. Antibody-based protein multiplex platforms: technical and operational challenges. Clin Chem. 2010;56(2):186-93.
69. Boja ES, Jortani SA, Ritchie J, Hoofnagle AN, Tezak Z, Mansfield E, et al. The journey to regulation of protein-based multiplex quantitative assays. Clin Chem. 2011;57:560-7.
70. Dick DM. Gene-environment interaction in psychological traits and disorders. Annu Rev Clin Psychol. 2011;7:383-409.
71. Fleischhacker W. Negative symptoms in patients with schizophrenia with special reference to the primary versus secondary distinction. Encephale. 2000;26 Spec No 1:12-4.
72. Dunayevich E, Keck PE Jr. Prevalence and description of psychotic features in bipolar mania. Curr Psychiatry Rep. 2000;2:286-90.
73. Ferrier IN, Stanton BR, Kelly TP, Scott J. Neuropsychological function in euthymic patients with bipolar disorder. Br J Psychiatry. 1999;175:246-51.
74. Gallien S, Duriez E, Domon B. Selected reaction monitoring applied to proteomics. J Mass Spectrom. 2011;46:298-312.
75. Bhatta D, Christie G, Madrigal-González B, Blyth J, Lowe CR. Holographic sensors for the detection of bacterial spores. Biosens Bioelectron. 2007;23:520-7.
76. Kabilan S, Marshall AJ, Sartain FK, Lee MC, Hussain A, Yang X, et al. Holographic glucose sensors. Biosens Bioelectron. 2005;20:1602-10.
77. Sartain FK, Yang X, Lowe CR. Holographic lactate sensor. Anal Chem. 2006;78:5664-70.
78. Tan EV, Lowe CR. Holographic enzyme inhibition assays for drug discovery. Anal Chem. 2009;81:7579-89.
79. Millan E. The value of the schizophrenia diagnostic market. Masters of Business Administration Individual Project (Judge Business School, Cambridge University). MBA thesis; 2007.
80. Kelly D, Thedford S, Vyas G. A new blood-based diagnostic aid for schizophrenia. Psychiatr Serv. 2011;62:1107.
81. Poste G. Bring on the biomarkers. Nature. 2011;469:156-7.